Candel Therapeutics, Inc. (CADL) intrinsic value & 10-year financials
Candel Therapeutics, Inc. (CADL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.19
- Market cap
- $433.7M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- 0.0%
- ROIC (10-yr avg)
- 165.7%
- Free cash flow (FY2025)
- -$38.9M
CADL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$38.2M | -$0.72 | -$38.9M | — | 106.5% |
| FY2024 | — | -$55.2M | -$1.74 | -$27.0M | — | 262.1% |
| FY2023 | — | -$37.9M | -$1.31 | -$34.7M | — | 348.6% |
| FY2022 | $125.0K | -$18.8M | -$0.65 | -$32.7M | -27777.6% | 179.0% |
| FY2021 | $125.0K | -$36.1M | -$1.91 | -$24.1M | -20580.8% | 67.6% |
| FY2020 | $125.0K | -$17.7M | — | -$10.5M | -11048.0% | 30.4% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Candel Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Candel Therapeutics, Inc. has earned high returns on invested capital, averaging 35.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Candel Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Candel Therapeutics, Inc. is modeled at 0.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-5.28 per share.